-
公开(公告)号：US20230119013A1
公开(公告)日：2023-04-20
申请号：US17914414
申请日：2021-04-07
Applicant: MISSION THERAPEUTICS LIMITED
Inventor： Christopher Andrew LUCKHURST , Mark Ian KEMP , Paul William THOMPSON
IPC: A61K31/421 , A61P43/00
Abstract: The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis.
-
Patent Agency Ranking
![1-(5-(2-CYANOPYRIDIN-4-YL)OXAZOLE-2-CARBONYL)-4-METHYLHEXAHYDROPYRROLO[3,4-B]PYR ROLE-5(1H)-CARBONITRILE AS USP30 INHIBITOR FOR USE IN THE TREATMENT OF MITOCHONDRIAL DYSFUNCTION, CANCER AND FIBROSIS](/abs-image/US/2023/10/05/US20230312580A1/abs.jpg.150x150.jpg)
公开(公告)号：US20230312580A1
公开(公告)日：2023-10-05
申请号：US18008352
申请日：2021-06-07
Applicant: MISSION THERAPEUTICS LIMITED
Inventor： Christopher Andrew LUCKHURST , Mark Ian KEMP , Paul William THOMPSON , Martin Lee STOCKLEY
IPC: C07D487/04 , C07D417/12 , A61P11/00 , A61P1/16 , A61P25/28 , A61P13/12
CPC classification number: C07D487/04 , A61P1/16 , A61P11/00 , A61P13/12 , A61P25/28 , C07D417/12
Abstract: The present invention relates to hexahydropyrrolo[3,4-b]pyrrole-5(1H)-carbonitriles with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis:.
-
公开(公告)号：US20230303547A1
公开(公告)日：2023-09-28
申请号：US18007641
申请日：2021-06-03
Applicant: MISSION THERAPEUTICS LIMITED
Inventor： Christopher Andrew LUCKHURST , Mark Ian KEMP , Paul William THOMPSON
IPC: C07D413/12 , A61P13/12 , A61P19/04
CPC classification number: C07D413/12 , A61P13/12 , A61P19/04
Abstract: The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquity lating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: (formulae (I)(i) and (I)(ii)).
-
公开(公告)号：US20250034122A1
公开(公告)日：2025-01-30
申请号：US18712785
申请日：2022-11-30
Applicant: MISSION THERAPEUTICS LIMITED
Inventor： Mark Ian KEMP , Christopher Andrew LUCKHURST
IPC: C07D413/14 , A61K31/4155 , A61K31/416 , A61K31/4192 , A61K31/422 , A61K31/4245 , A61K31/4439 , C07D401/14 , C07D403/14
Abstract: The present invention relates to a class of substituted N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: Formula (I).
-
公开(公告)号：US20230219939A1
公开(公告)日：2023-07-13
申请号：US17927053
申请日：2021-05-27
Applicant: MISSION THERAPEUTICS LIMITED
Inventor： Christopher Andrew LUCKHURST , Mark Ian KEMP , Paul William THOMPSON
IPC: C07D413/12 , A61P13/12
CPC classification number: C07D413/12 , A61P13/12
Abstract: The present invention relates to a class of N-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: Formula (I), Formula (II).
-
公开(公告)号：US20220315572A1
公开(公告)日：2022-10-06
申请号：US17639015
申请日：2020-09-03
Applicant: MISSION THERAPEUTICS LIMITED
Inventor： Paul William THOMPSON , Christopher Andrew LUCKHURST , Mark Ian KEMP
Abstract: The present invention relates to a class of substituted-cyanopyrrolidines with activity as inhibitors of the deubiquitylating enzyme USP30, having utility in a variety of therapeutic areas, including conditions involving mitochondrial dysfunction, cancer and fibrosis: (I).
-
-
-
-
-
Search Results
6
records
(took 0.016 seconds)
